Virus Or Bacteriophage, Except For Viral Vector Or Bacteriophage Vector; Composition Thereof; Preparation Or Purification Thereof; Production Of Viral Subunits; Media For Propagating Patents (Class 435/235.1)
  • Patent number: 9765139
    Abstract: Production of etanercept using perfusion methods achieves attractive yields of properly folded protein. Desired temperature, feed media, titers and percent correctly folded protein are disclosed.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: September 19, 2017
    Assignee: Coherus Biosciences, Inc.
    Inventors: Ela Puchacz, James Russell Grove
  • Patent number: 9738690
    Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: August 22, 2017
    Assignee: UNIVERSITAET ZUERICH
    Inventors: Ilijas Jelcic, Roland Martin, Sven Schippling, Mireia Sospedra, Sara Yousef
  • Patent number: 9732144
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: August 15, 2017
    Assignee: Ohio State Innovation Foundation
    Inventor: Daral John Jackwood
  • Patent number: 9724404
    Abstract: The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: August 8, 2017
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Aura Biosciences, Inc.
    Inventors: Pierre L. Coursaget, Antoine A. Touzé, Maxime J. J. Fleury, Nicolas Combelas, Elisabet de los Pinos
  • Patent number: 9713639
    Abstract: The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing PEDV antigens. The invention also encompasses recombinant vectors encoding and expressing PEDV antigens, epitopes or immunogens which can be used to protect porcine animals against PEDV.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: July 25, 2017
    Assignee: MERIAL, INC.
    Inventors: Paulraj Lawrence, Russell Bey
  • Patent number: 9714435
    Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors. In particular, the present invention provides an adenovirus vector comprising a capsid derived from chimpanzee adenovirus AdY25, wherein said capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: July 25, 2017
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
  • Patent number: 9708627
    Abstract: The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: July 18, 2017
    Assignee: UNIQURE IP B.V.
    Inventors: Wilhelmus Theodorus Johannes Maria Christiaan Hermens, Saskia Jacoba Petronella Haast, Dennis Johan Biesmans, Andrew Christian Bakker
  • Patent number: 9701945
    Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: July 11, 2017
    Assignee: Valneva
    Inventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
  • Patent number: 9694066
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: July 4, 2017
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 9663766
    Abstract: Methods of purifying an adenovirus from an impure preparation are provided. In some embodiments, a combination of mixed mode chromatography and anion exchange chromatography is used to purify the adenovirus.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: May 30, 2017
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Mark Irwin Fitchmun
  • Patent number: 9650612
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: May 16, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Patent number: 9650682
    Abstract: Briefly described, embodiments of the present disclosure relate to methods and systems for identifying and classifying taxa of organohalide-respiring bacteria, including methods and systems for identify and classify two or more taxa of Dehalococcoides.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: May 16, 2017
    Inventors: Alfred M. Spormann, Ian Philip George Marshall
  • Patent number: 9629877
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 25, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence JN Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
  • Patent number: 9617328
    Abstract: Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: April 11, 2017
    Assignee: SK CHEMICALS CO., LTD.
    Inventors: Min Sun Lee, Hun-Taek Kim, Bong-yong Lee, Mahn Hoon Park, Yun Jung Lim
  • Patent number: 9597377
    Abstract: This application provides methods of improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered. The application further provides stable compositions comprising the purified protein and an ASSC, and methods of treatment by administering the compositions.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: March 21, 2017
    Assignee: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY
    Inventor: Jian-Qiang Fan
  • Patent number: 9597415
    Abstract: Provided herein are methods for expressing a polynucleotide of interest in the retina of a subject. In particular, a method for expressing a polynucleotide of interest in the retina of a subject comprising the step consisting of injecting into the vitreous an amount of a vector containing the polynucleotide of interest in combination with an amount of an inhibitor of Dp71 expression is provided.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: March 21, 2017
    Assignees: INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Deniz Dalkara, Alvaro Rendon Fuentes, Jose Alain Sahel, Ophelie Vacca
  • Patent number: 9591858
    Abstract: At least one novel virus capable of infecting crazy ants (Nylanderia fulva) is isolated, along with polynucleotide sequences and amino acid sequences of the virus. The virus is capable of be used as a biopesticide to control populations of crazy ants.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: March 14, 2017
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Steven M. Valles, David H. Oi
  • Patent number: 9580691
    Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: February 28, 2017
    Assignee: UNIQURE IP B.V.
    Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
  • Patent number: 9575070
    Abstract: A diagnostic device for and method of detecting the presence of head and neck squamous cell carcinoma (HNSCC) in a patient including a detector device for detecting a presence of at least one marker indicative of HNSCC, the detector device including a panel of markers for HNSCC. A diagnostic device for and method of staging HNSCC in a patient including a detector device for detecting a presence of at least one marker indicative of stages of HNSCC, the detector device including a panel of markers for HNSCC. Markers for head and neck squamous cell carcinoma selected from the markers listed in Table 5. Methods of personalized immunotherapy, making a personalized anti-cancer vaccine, and predicting a clinical outcome in a HNSCC patient. A method of making a panel of HNSCC markers.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: February 21, 2017
    Assignee: Wayne State University
    Inventors: Michael A. Tainsky, Sorin Draghici, Ho-Sheng Lin
  • Patent number: 9550998
    Abstract: The present invention relates to the production and use of covalently closed circular (ccc) recombinant plasmids, and more particularly to vector modifications that improve expression of said DNA molecules in the target organism.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 24, 2017
    Assignee: NATURE TECHNOLOGY CORPORATION
    Inventor: James A. Williams
  • Patent number: 9527081
    Abstract: Devices and methods for delivering a chimeric deoxyribonucleic acid (DNA) marking agent to a target and identifying the target from the chimeric DNA marking agent are provided. A delivery device may be a projectile, a spray canister or a wet/dry article. The chimeric DNA marking agent includes unique DNA fragments and may also include a fill material such as a liquid, a gas or a powder. The chimeric DNA marking agent may be combined with any combination of general marking agent, an inhibiting agent, an immobilizing agent, a weighting agent and a protective agent. The DNA marking agent may be analyzed using any of a hybridization method utilizing a labeled probe, a gel electrophoresis method, determining the base sequence to confirm a predefined DNA sequence, amplifying at least one of the unique DNA fragments and using a polymerase chain reaction (PCR) method.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: December 27, 2016
    Assignee: UNITED TACTICAL SYSTEMS, LLC
    Inventors: Gary E. Gibson, Benjamin Tyler Tiberius
  • Patent number: 9511135
    Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: December 6, 2016
    Assignee: STC.UNM
    Inventors: Bryce C. Chackerian, David S. Peabody
  • Patent number: 9504762
    Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: November 29, 2016
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Peter Cameron Colosi, Amit Nathwani, Jenny Mcintosh, Edward Tuddenham
  • Patent number: 9486007
    Abstract: A system and method for reducing or preventing bacterial contamination in food includes application of a bacteriophage treatment to any type of food product at any stage of processing the food product. The bacteriophage treatment may also be applied to non-food surfaces and water systems, which may be susceptible to bacterial contamination and subsequent spread of bacteria. The bacteriophage treatment comprises at least one bacteriophage in a concentration sufficient to reduce or prevent bacterial contamination from pathogenic bacteria and/or spoilage bacteria. In some embodiments, the bacteriophage is able to reduce or eliminate bacteria introduced to a food product after the bacteriophage treatment was applied to the food product. In some embodiments, the bacteriophage treatment includes a buffering agent to maintain the bacteriophage at a pH level that sustains the bacteriophage. In some embodiments, the bacteriophage treatment includes a surfactant and/or a thickener to aid in applying the bacteriophage.
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: November 8, 2016
    Assignee: Ecolab USA Inc.
    Inventors: Scott L. Burnett, Timothy A. Gutzmann, Bruce R. Cords
  • Patent number: 9475845
    Abstract: The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: October 25, 2016
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Aravind Asokan, Richard Jude Samulski
  • Patent number: 9464119
    Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3. Furthermore, the invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z. The invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: October 11, 2016
    Assignees: Deutsches Krebsforschungszentrum, Medigene AG
    Inventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Lux
  • Patent number: 9464276
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: October 11, 2016
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael Massare, Peter Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • Patent number: 9409973
    Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: August 9, 2016
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Xavier Saelens, Bert Schepens, Walter Fiers
  • Patent number: 9404089
    Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: August 2, 2016
    Assignees: Zoctis Services LLC, Intrlytix Inc.
    Inventors: Jeremy Mathers, Alexander Sulakvelidze
  • Patent number: 9404090
    Abstract: The invention relates to a cell line in which an expression construct is introduced into genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus El coding gene sequence of SEQ ID NO: 32 operatively linked to the promoter. The cell line of the invention is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the invention shows superior adenovirus producing ability, as compared with an HEK 293 cell which is one of conventional adenovirus producing cell lines.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: August 2, 2016
    Assignee: VIROMED CO., LTD.
    Inventors: Seung Shin Yu, Chang-Wan Joo, Jin-A Chae, Yeon Suk Cha
  • Patent number: 9387242
    Abstract: The present invention provides chimeric negative-stand RNA viruses that allow a subject, e.g., an avian, to be immunized against two infectious agents by using a single chimeric virus of the invention. In particular, the present invention provides chimeric influenza viruses engineered to express and incorporate into their virions a fusion protein comprising an ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an influenza virus protein. Such chimeric viruses induce an immune response against influenza virus and the infectious agent. The present invention also provides chimeric Newcastle Disease viruses (NDV) engineered to express and incorporate into their virions a fusion protein comprising the ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an NDV protein. Such chimeric viruses induce an immune response against NDV and the infectious agent.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: July 12, 2016
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Peter Palese, Adolfo Garcia-Sastre
  • Patent number: 9388380
    Abstract: The present invention relates to a method for production of continuous cell lines comprising providing living cells of an animal or a human, irradiating said cells with UV light, proliferating said cells and selecting multiplying cells as cells of a continuous cell line.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: July 12, 2016
    Assignee: NANOTHERAPEUTICS, INC.
    Inventors: Manfred Reiter, Wolfgang Mundt, Simone Feigl, Simone Von Fircks
  • Patent number: 9387241
    Abstract: Influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these VLPs as well as methods of making and using these VLPs.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: July 12, 2016
    Assignee: TechnoVax, Inc.
    Inventors: Jose M. Galarza, Demetrius Matassov
  • Patent number: 9381240
    Abstract: The present disclosure teaches generally in the field of vaccination and disease control in cattle and bovine animals. A recombinant bovine herpesvirus 1 (BoHV-1) vaccine vector is provided for efficient control of one or more bovine pathogens such as those associated with bovine respiratory disease complex, such as bovine viral diarrhea virus (BVDV), and which ameliorates disease conditions caused thereby. Protocols for the management of confined or herded bovine animals are also enabled herein.
    Type: Grant
    Filed: July 4, 2012
    Date of Patent: July 5, 2016
    Assignees: THE STATE OF QUEENSLAND ACTING THROUGH THE DEPARTMENT OF AGRICULTURE AND FISHERIES, MEAT & LIVESTOCK AUSTRALIA LIMITED
    Inventor: Timothy John Mahony
  • Patent number: 9381239
    Abstract: The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: July 5, 2016
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Peter Pushko, Kutub Mahmood, Bin Zhou
  • Patent number: 9343802
    Abstract: An antenna of a communication device includes a metal frame, a metal back cover and a printed circuit board. The printed circuit board includes a first circuit block and a second circuit block electrically connected to the first circuit block. A first conductor is connected between a first part of the metal frame and a signal terminal of the first circuit block. A second conductor is connected between a second part of the metal frame and a ground terminal of the first circuit block. A third conductor is connected to a third part of the metal frame. A fourth conductor is connected to a ground terminal of the second circuit block, and at least one coupling gap is defined between the third conductor and the fourth conductor. A signal terminal of the second circuit block is electrically connected to a fourth part of the metal frame.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: May 17, 2016
    Assignee: KING SLIDE TECHNOLOGY CO., LTD.
    Inventors: Hsin-Cheng Su, Chun-Ta Liu, Shu-Chen Lin
  • Patent number: 9265843
    Abstract: Described herein is a system which uses a gene therapy particle that includes at least one gene, cDNA, fragment or analogue of at least one neurotropin that binds to the trkB receptor or the trkB receptor itself. The gene therapy particle is capable of being delivered to a subject in need thereof for therapy of a metabolic disorder. In a particular aspect, this invention is directed to an inventive method that demonstrates a remarkable efficacy on lowering body weight.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: February 23, 2016
    Assignee: The Ohio State University
    Inventors: Matthew J. During, Lei Cao
  • Patent number: 9260724
    Abstract: The present invention relates to the improved production of recombinant parvoviral virions in insect cells. In particular, the invention relates to an improved process for the production of recombinant parvoviral virions in insect cells, wherein the full/empty parvoviral virion ratio is increased. The invention also relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral Rep proteins that increase the productivity of parvoviral vectors.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: February 16, 2016
    Assignee: UNIQURE IP B.V.
    Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria Christiaan Maria Christ Hermens, Yvet Noordman
  • Patent number: 9255254
    Abstract: At least one novel virus capable of infecting crazy ants (Nylanderia fulva) is isolated, along with polynucleotide sequences and amino acid sequences of the virus. The virus is capable of be used as a biopesticide to control populations of crazy ants.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 9, 2016
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Steven M. Valles, David H. Oi
  • Patent number: 9254318
    Abstract: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes at least five internal genes from an influenza virus isolate that replicates to high titers in embryonated chicken eggs or MDCK cells.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: February 9, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Yoshihiro Kawaoka, Taisuke Horimoto, Shin Murakami
  • Patent number: 9206440
    Abstract: The present invention relates to compositions and methods for creation of vector nucleic acid sequences (e.g., retroviral nucleic acid sequences) that comprise two or more exogenous nucleic acid sequences that encode highly homologous (e.g., identical) polypeptide sequences, yet wherein at least one of the exogenous nucleic acid sequences has been mutated using degenerate codons for purpose of reducing homology between the two or more exogenous nucleic acid sequences while maintaining the encoded polypeptide sequence. Preferred nucleic acid sequences include those encoding multi-chimeric immune receptor (CIR) genes. Specific nucleic acid sequences of such CIR genes are also disclosed.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: December 8, 2015
    Assignee: ROGER WILLIAMS HOSPITAL
    Inventors: Wen Yang, Richard P. Junghans, Anthony J. Bais
  • Patent number: 9180181
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: November 10, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 9169494
    Abstract: This invention relates to modified parvovirus inverted terminal repeats (ITRs) that do not functionally interact with wild-type large Rep proteins, synthetic Rep proteins that functionally interact with the modified ITRs, and methods of using the same for delivery of nucleic acids to a cell or a subject. The modifications provide a novel Rep-ITR interaction that limits vector mobilization, increasing the safety of viral vectors.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: October 27, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Curtis Hewitt, Richard Jude Samulski
  • Patent number: 9163211
    Abstract: The present invention relates to animal protein free cell culture media comprising a combination of non-animal derived peptides derived from soy hydrolysate and yeast hydrolysate. The invention also provides an animal protein free culture process, wherein cells are cultivated, propagated and passaged without animal-derived components. This process is useful for cultivating cells, such as recombinant cells or cells infected with a virus, and for production biological products by cell culture processes under conditions devoid of animal protein components.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: October 20, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Manfred Reiter, Wolfgang Mundt, Leopold Grillberger, Barbara Kraus
  • Patent number: 9163067
    Abstract: Isolated peptides comprising sequences derived from the protein integrase of HIV-1, as well as their analogs, mixtures, conjugates with permeability enhancing moieties, and pharmaceutical compositions are disclosed. The peptides and compositions are capable of selectively killing HIV-1 infected cells and are used in treatment of HIV infection and AIDS.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: October 20, 2015
    Assignee: Yissum Research Development Company of The Hebrew University of Jerusalem Ltd
    Inventors: Aviad Levin, Zvi Hayouka, Assaf Friedler, Abraham Loyter
  • Patent number: 9101653
    Abstract: The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: August 11, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Yoshihiro Kawaoka, Gabriele Neumann, Makoto Ozawa
  • Patent number: 9090873
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3?untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5?direction as far as the 5?boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: July 28, 2015
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
  • Patent number: 9068159
    Abstract: There is provided a bacteriophage capable of lysing a P. acnes bacterium and incapable of lysing a bacterium which is not P. acnes, and which is incapable of sustaining lysogeny in a bacterium. There is also provided a pharmaceutical composition comprising such a bacteriophage.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: June 30, 2015
    Assignee: MICREOS B.V.
    Inventors: Keith Holland, Richard Bojar, David West
  • Patent number: 9068986
    Abstract: The present invention encompasses methods of producing influenza B viruses in cell culture. The influenza B viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza B virus infection.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: June 30, 2015
    Assignee: MedImmune, LLC
    Inventors: Hong Jin, Zhongying Chen
  • Patent number: RE46042
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: June 28, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai